Lv6
2338 积分 2021-06-15 加入
P3.12.38 Updated Clinical Results From FURTHER: A Study of Firmonertinib in TKI-Naive, Advanced NSCLC With EGFR PACC Mutations
7天前
已关闭
EML4‐ALK G1202R and EML4‐ALK L1196M mutations induce crizotinib resistance in non‐small cell lung cancer cells through activating epithelial–mesenchymal transition mediated by MDM2/MEK/ERK signal axis
8天前
已完结
Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis
8天前
已完结
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs
8天前
已完结
Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC
8天前
已完结
Resistance mechanisms in anaplastic lymphoma kinase-positive lung cancer
8天前
已完结
ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms race
8天前
已完结
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
14天前
已完结
POLE-mutated Endometrial “Carcinosarcoma”
19天前
已关闭
Pelvic Carcinosarcoma Showing a Diverse Histology and Hierarchical Gene Mutation with a Common POLE Mutation to Endometrial Endometroid Carcinoma: A Case Report
19天前
已完结
皖公网安备34019202002308
